<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>When to initiate antiretroviral therapy in persons with HIV</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">When to initiate antiretroviral therapy in persons with HIV</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">When to initiate antiretroviral therapy in persons with HIV</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul E Sax, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Martin S Hirsch, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer Mitty, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 22, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Epidemiologic data have demonstrated that combination antiretroviral therapy (ART) has led to remarkable declines in morbidity and mortality among persons with human immunodeficiency virus (HIV) [<a href="#rid1">1-3</a>]. Initially, there was a "hit hard and hit early" approach to treatment, implying that all patients should be treated with combination therapy as soon as possible [<a href="#rid4">4</a>]. Some providers, however, withheld therapy in patients with relatively preserved CD4 counts given the toxicity and complexity of early ART and the lack of clinical evidence proving a benefit of therapy for those with normal CD4 counts. Definitive clinical trials and further advances in HIV therapy have shifted the risk-benefit ratio back to earlier treatment. The standard of care today is to treat nearly all HIV-infected individuals with ART, regardless of CD4 count. </p><p>This topic will discuss when to initiate ART and will review the evidence supporting rapid initiation of therapy. The selection of specific medications and laboratory monitoring on treatment are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3773.html" rel="external">"Selecting antiretroviral regimens for treatment-naïve persons with HIV-1: General approach"</a> and  <a class="medical medical_review" href="/z/d/html/3770.html" rel="external">"Patient monitoring during HIV antiretroviral therapy"</a>.) </p><p class="headingAnchor" id="H27016986"><span class="h1">UNIVERSAL TREATMENT</span></p><p class="headingAnchor" id="H3414499025"><span class="h2">Treatment regardless of CD4 count</span><span class="headingEndMark"> — </span>We recommend antiretroviral therapy (ART) for patients with HIV infection and a detectable viral load, regardless of CD4 count. This approach is supported by guideline panels [<a href="#rid5">5,6</a>]. The benefits of ART are discussed below. (See <a class="local">'Benefits of antiretroviral therapy'</a> below.)</p><p>Considerations for treatment of HIV controllers, a small subset of patients who are able to maintain plasma HIV RNA at levels below the level of detection without ART, are discussed below. (See <a class="local">'HIV controllers'</a> below.) </p><p>Previous recommendations for ART in persons with low CD4 counts (eg, &lt;350 cells/microL) were heavily influenced by drug toxicities, inconvenience, the potential risk for drug resistance if virologic suppression was not achieved, and limited treatment options for patients who failed therapy. Therapeutic options have now expanded, and the available agents are more potent, better tolerated, and associated with less toxicity compared with earlier agents. In addition, simplified regimens have led to improved adherence, which decreases the risk of developing virologic failure with drug-resistant virus. (See  <a class="medical medical_review" href="/z/d/html/3773.html" rel="external">"Selecting antiretroviral regimens for treatment-naïve persons with HIV-1: General approach"</a> and  <a class="medical medical_review" href="/z/d/html/13978.html" rel="external">"Overview of antiretroviral agents used to treat HIV"</a>.) </p><p class="headingAnchor" id="H2509934491"><span class="h2">Benefits of antiretroviral therapy</span><span class="headingEndMark"> — </span>In persons with HIV, antiretroviral therapy (ART) reduces mortality as well as serious acquired immunodeficiency syndrome (AIDS)- and non-AIDS-related complications. Patients without other significant comorbidities who are treated before significant immunosuppression can expect a life expectancy approaching that of the general population [<a href="#rid7">7,8</a>]. Treatment also prevents transmission of HIV to others. (See <a class="local">'Reduction in HIV transmission'</a> below.)</p><p class="headingAnchor" id="H1356387689"><span class="h3">Reduction in mortality and morbidity</span><span class="headingEndMark"> — </span>For patients with HIV, effective ART results in sustained suppression of HIV RNA. This leads to improvements in cellular immunity (eg, CD4 count) and a subsequent reduction in AIDS-related morbidity and mortality. Suppression in HIV RNA can also result in a reduction in HIV immune activation (eg, proinflammatory cytokines, chronic inflammation, and T-cell activation), which can otherwise lead to end-organ damage (eg, coronary artery disease, liver and kidney disease, malignancy, neurologic disease) [<a href="#rid9">9</a>]. </p><p>The benefit of ART for individuals with HIV, regardless of CD4 count or the presence of symptoms, was suggested by a large cohort study that described reduced mortality among those who received ART when the CD4 count was &gt;500 cells/microL compared with starting treatment below this threshold [<a href="#rid10">10</a>]. Two large randomized clinical trials have subsequently supported this approach based upon favorable clinical outcomes without an increase in adverse events [<a href="#rid11">11,12</a>]. (See <a class="local">'Patients with a CD4 count &gt;350 cells/microL'</a> below.)</p><p>However, the patient's baseline CD4 count can impact treatment outcomes. This was illustrated in a collaborative study of 62,760 treatment-naïve patients in Europe and the United States [<a href="#rid13">13</a>]. Over a mean follow-up of 3.3 years, 2039 patients died. Although the overall risk of mortality was reduced by approximately 50 percent among those who initiated ART compared with those who did not, the absolute survival benefit depended upon the patient's level of immunocompromise before treatment. </p><p>More detailed information on the benefits of ART is found below. (See <a class="local">'Patients with a CD4 count ≤350 cells/microL'</a> below and <a class="local">'Patients with a CD4 count &gt;350 cells/microL'</a> below.)</p><p class="headingAnchor" id="H84590462"><span class="h4">Patients with a CD4 count ≤350 cells/microL</span><span class="headingEndMark"> — </span>There is high-quality evidence that initiating ART in patients with a CD4 count ≤350 cells/microL results in a significant decline in the risk of AIDS-related morbidity and mortality [<a href="#rid10">10,14-28</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span>In patients with AIDS (ie, a CD4 count &lt;200 cells/microL and/or a history of an AIDS-defining illness), clinical trials have clearly demonstrated that ART improves survival and delays disease progression [<a href="#rid16">16,28</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Initiating ART in patients with higher CD4 counts (<strong>before</strong> the CD4 count is &lt;200 cells/microL) also reduces mortality in individuals with HIV. In a randomized clinical trial of 816 patients from Haiti, patients who initiated ART treatment when the CD4 count was &lt;200 cells/microL had a higher mortality rate compared with those who initiated ART when the CD4 count was between 200 and 350 cells/microL (23 versus 6 deaths; hazard ratio [HR] 4; 95% CI 1.6-9.8) [<a href="#rid26">26</a>].</p><p></p><p>In patients with a CD4 count &lt;350 cells/microL, the mortality benefit is mostly from a reduction in opportunistic and other infections.</p><p class="headingAnchor" id="H84590482"><span class="h4">Patients with a CD4 count &gt;350 cells/microL</span><span class="headingEndMark"> — </span>Initiating ART in patients with CD4 counts of &gt;350 cells/microL reduces serious AIDS- and non-AIDS-related complications. The best evidence for initiating ART in patients with a CD4 count &gt;350 cells/microL comes from the START and Temprano trials [<a href="#rid11">11,12</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span>The START trial evaluated early versus deferred ART in 4685 treatment-naïve men and women with HIV who were from low-, moderate-, and high-income countries and had CD4 counts &gt;500 cells/microL [<a href="#rid11">11</a>]. Individuals were randomly assigned to early initiation of ART (upon study entry) or delayed initiation (when the CD4 count reached 350 cells/microL). After approximately three years of follow-up, an interim analysis found the risk of a combined outcome that included AIDS-related events, serious non-AIDS events (eg, cancer, major cardiovascular, liver, and renal disease), or death was significantly reduced in individuals who received early compared with deferred therapy (1.8 versus 4.1 percent), leading to early termination of the deferred therapy arm. In both study groups, most events occurred when the CD4 count was &gt;500 cells/microL (94 of 138 events). Compared with the group that was assigned to deferred therapy (median CD4 count 408 at ART initiation), the group that was assigned to early ART (median CD4 count 651 at ART initiation) was significantly less likely to develop serious AIDS- (HR 0.28; 95% CI 0.15-0.50) or non-AIDS-related events (HR 0.61; 95% CI 0.38-0.97). </p><p></p><p class="bulletIndent1">The benefits of early ART were sustained over time, even after participants in the deferred therapy group were encouraged to initiate ART regardless of CD4 count [<a href="#rid29">29</a>]. During a median of 9.3 years of follow-up (from randomization through 2021), the risk of developing AIDS-related events, serious non-AIDS events, or death continued to be lower in the immediate versus deferred therapy group (HR 0.61; 95% CI, 0.49 to 0.76). Although the benefit of early ART diminished when all participants were offered ART (after January 1, 2016), there continued to be a lower number of adverse outcomes in the immediate therapy group (89 versus 113, respectively; HR 0.79 [95% CI, 0.60 to 1.04]). The continued benefit of early ART may be due in part to ongoing differences in immunologic recovery, as CD4 cell counts remained lower in the deferred therapy group (CD4 count difference 155 cells/microL from 2016 through 2021). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The TEMPRANO trial, which evaluated early versus deferred ART initiation (ie, at study entry versus World Health Organization criteria for ART initiation), enrolled 849 individuals with HIV from the Ivory Coast who had a CD4 count ≥500 cells/microL at study entry [<a href="#rid12">12</a>]. In both groups, the mean CD4 count at the onset of a primary endpoint (death from any cause, AIDS-defining disease, non-AIDS-defining cancer, or non-AIDS-defining invasive bacterial disease) was &gt;500 cells/microL. However, individuals assigned to early therapy were significantly less likely to develop an event compared with those who were assigned to deferred therapy (HR 0.56; 95% CI 0.33-0.94). </p><p></p><p class="headingAnchor" id="H3610370710"><span class="h3">Comorbid conditions</span><span class="headingEndMark"> — </span>Among patients with HIV, serious non-AIDS events are more common and associated with higher rates of mortality than AIDS-related events [<a href="#rid30">30,31</a>]. Factors that independently predict death due to non-AIDS events include diabetes, advanced age, and hepatitis B/hepatitis C status. </p><p>ART has resulted in both a decreased incidence of HIV-related comorbid conditions and an improvement in the outcomes among those who develop disease. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiovascular disease</strong> – HIV infection itself may accelerate atherosclerosis, and the incidence of coronary artery disease (eg, myocardial infarction [MI]) is higher in patients with HIV compared with patients without HIV who are matched for age and gender. Lower CD4 cell counts and higher HIV RNA levels have been associated with increased MI risk [<a href="#rid32">32</a>]. Although certain antiretroviral agents may be associated with an increased risk of MI (eg, <a class="drug drug_general" data-topicid="8993" href="/z/d/drug information/8993.html" rel="external">abacavir</a>, most protease inhibitors), most ART regimens do not increase the risk of MI, whereas untreated HIV does. (See  <a class="medical medical_review" href="/z/d/html/3734.html" rel="external">"Epidemiology of cardiovascular disease and risk factors in patients with HIV"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>HIV-associated nephropathy (HIVAN)</strong> – Initiation of ART has been associated with a dramatic decline in the incidence of HIVAN. In addition, ART in patients with HIVAN has been associated with both preserved/improved renal function and prolonged survival. (See  <a class="medical medical_review" href="/z/d/html/14026.html" rel="external">"HIV-associated nephropathy (HIVAN)", section on 'Antiretroviral therapy for all patients'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>HIV-associated neurocognitive disorders (HAND)</strong> – Effective ART is the primary treatment of HAND. ART has been associated with improvement in cognitive function in certain patients and may prevent further impairment. (See  <a class="medical medical_review" href="/z/d/html/98405.html" rel="external">"HIV-associated neurocognitive disorders: Management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hepatitis B or C coinfection</strong> – HIV infection is associated with more rapid progression of viral hepatitis-related liver disease, including cirrhosis, end-stage liver disease, hepatocellular carcinoma, and fatal hepatic failure. Progression of liver disease may be slower in such patients with hepatitis B or hepatitis C coinfection taking ART. In addition, in patients with HIV/HCV coinfection, ART is associated with reductions in nonopportunistic infection-related deaths [<a href="#rid33">33,34</a>]. (See  <a class="medical medical_review" href="/z/d/html/3652.html" rel="external">"Treatment of chronic hepatitis B in patients with HIV"</a> and  <a class="medical medical_review" href="/z/d/html/3701.html" rel="external">"Treatment of chronic hepatitis C virus infection in the patient with HIV"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tuberculosis</strong> – ART reduces the risk of developing tuberculosis in patients with HIV, although incidence rates remain higher than in the general population. ART also improves treatment outcomes among those with tuberculosis in both resource-rich and resource-limited countries. (See  <a class="medical medical_review" href="/z/d/html/8013.html" rel="external">"Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults with HIV infection: Initiation of therapy"</a> and  <a class="medical medical_review" href="/z/d/html/111683.html" rel="external">"Diagnosis of pulmonary tuberculosis in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Malignancy</strong> – With the widespread introduction of ART, the incidence of Kaposi sarcoma and lymphoma has declined. Reductions in HIV viral load and improvements in immune function associated with ART have also been associated with improved clinical outcomes in patients with these tumors [<a href="#rid35">35</a>] and can result in an improved ability to tolerate chemotherapy and fewer opportunistic infections. (See  <a class="medical medical_review" href="/z/d/html/8034.html" rel="external">"AIDS-related Kaposi sarcoma: Staging and treatment", section on 'Treatment'</a> and  <a class="medical medical_review" href="/z/d/html/8035.html" rel="external">"HIV infection and malignancy: Epidemiology and pathogenesis"</a> and  <a class="medical medical_review" href="/z/d/html/8036.html" rel="external">"HIV infection and malignancy: Management considerations"</a>.) </p><p></p><p class="bulletIndent1">The strongest evidence demonstrating a reduced risk of AIDS-related malignancy from early ART comes from the START study, described above [<a href="#rid11">11</a>]. In this study, there was a significant reduction in infection-related cancers (ie, those associated with human herpesvirus 8, Epstein-Barr virus, and human papillomavirus) among those receiving early ART (6 versus 23; HR 0.26, 95% CI 0.11-0.64) [<a href="#rid36">36</a>]. There was also a nonsignificant decrease in the risk of infection-unrelated cancers (8 versus 16; HR 0.49, 95% CI 0.21-1.15); however other data suggest that the rate of non-AIDS malignancies is stable or increasing [<a href="#rid31">31</a>].</p><p></p><p class="headingAnchor" id="H84590753"><span class="h3">Reduction in HIV transmission</span><span class="headingEndMark"> — </span>In patients with virologic suppression on ART, the risk of sexual transmission to others is eliminated. For pregnant women, ART can prevent perinatal HIV transmission. Detailed discussions of the use of antiretroviral treatment to prevent HIV transmission are found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/16612.html" rel="external">"HIV infection: Risk factors and prevention strategies"</a> and  <a class="medical medical_review" href="/z/d/html/15799.html" rel="external">"Antiretroviral selection and management in pregnant individuals with HIV in resource-rich settings"</a>.)</p><p class="headingAnchor" id="H1783534737"><span class="h1">TIMING OF TREATMENT</span><span class="headingEndMark"> — </span>For most individuals, we initiate antiretroviral therapy (ART) soon after their diagnosis. There are few reasons to delay ART when starting a tenofovir-based regimen with a high barrier to resistance. (See <a class="local">'Approach for most patients'</a> below.)</p><p>Special considerations in the following groups are discussed below:</p><p class="bulletIndent1"><span class="glyph">●</span>(See <a class="local">'Patients with acute symptomatic HIV infection'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See <a class="local">'Patients with opportunistic infections'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See <a class="local">'Pregnant persons'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See <a class="local">'HIV controllers'</a> below.)</p><p></p><p class="headingAnchor" id="H3590176085"><span class="h2">Approach for most patients</span><span class="headingEndMark"> — </span>For most patients, we suggest ART be prescribed within seven days of a confirmed HIV diagnosis, including on the same day, if feasible [<a href="#rid5">5</a>]. Rapid initiation of ART is associated with improved virologic outcomes and improved retention in care.</p><p>Treatments regimens for rapid ART initiation should be tenofovir-based and have a high barrier to resistance (eg, <a class="drug drug_general" data-topicid="116731" href="/z/d/drug information/116731.html" rel="external">bictegravir-emtricitabine-tenofovir alafenamide</a>, <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">dolutegravir</a> plus <a class="drug drug_general" data-topicid="107645" href="/z/d/drug information/107645.html" rel="external">tenofovir alafenamide-emtricitabine</a>, or pharmacologically boosted <a class="drug drug_general" data-topicid="8842" href="/z/d/drug information/8842.html" rel="external">darunavir</a> plus tenofovir alafenamide-emtricitabine). In this setting, ART can be initiated even if all baseline laboratory test results are not yet available (eg, basic metabolic panel, CD4 count, HIV resistance genotype, hepatitis B serology). By contrast, regimens that contain <a class="drug drug_general" data-topicid="8993" href="/z/d/drug information/8993.html" rel="external">abacavir</a> or non-nucleoside reverse transcriptase inhibitors (NNRTIs) and nucleoside reverse transcriptase inhibitor (NRTI)-sparing regimens should<strong> not</strong> be used for rapid ART initiation if baseline testing is not available, since this information should be reviewed before one of these regimens is initiated. (See  <a class="medical medical_review" href="/z/d/html/3773.html" rel="external">"Selecting antiretroviral regimens for treatment-naïve persons with HIV-1: General approach", section on 'Considerations prior to initiating treatment'</a>.)</p><p>A brief delay in initiating ART is reasonable if there is concern for an active comorbid condition or an active opportunistic infection that makes starting ART difficult (eg, concerns for drug interactions or overlapping toxicity). However, most patients should initiate ART within two weeks of diagnosis. (See <a class="local">'Patients with opportunistic infections'</a> below.)</p><p>For patients who have barriers to taking daily therapy (eg, because of substance use disorder, depression, homelessness), we typically do not delay ART. In such patients, we initiate an ART regimen with a high barrier to developing resistance while addressing the specific adherence concerns. </p><p>In low- and middle-income countries, same-day initiation of ART has been associated with improved virologic outcomes and improved retention in care [<a href="#rid37">37-39</a>]. In a meta-analysis of rapid ART initiation within one week of diagnosis, including seven randomized studies with 18,011 participants, there was greater viral suppression (risk ratio [RR] 1.18; 95% CI 1.10-1.27) and better ART uptake (RR 1.09; 95% CI 1.06-1.12) at 12 months compared with standard of care [<a href="#rid40">40</a>]. In resource-rich environments, observational studies have demonstrated that same-day ART is feasible, safe, and can reduce time to virologic suppression by one to two months [<a href="#rid41">41,42</a>].</p><p>Although all populations can benefit from early ART, it is particularly important for patients with low CD4 counts (eg, a CD4 count ≤200 cells/microL). Such persons are at the greatest risk for AIDS-related complications, and delayed ART can lead to a suboptimal virologic and immunologic response to treatment [<a href="#rid43">43-49</a>]. (See <a class="local">'Benefits of antiretroviral therapy'</a> above.)</p><p class="headingAnchor" id="H3529893136"><span class="h2">Considerations for specific populations</span></p><p class="headingAnchor" id="H3496659333"><span class="h3">Patients with acute symptomatic HIV infection</span><span class="headingEndMark"> — </span>For patients with acute symptomatic HIV infection, we initiate ART as soon as possible. If resources allow, initiation of ART on the same day of diagnosis can be a safe and effective treatment strategy. Early ART can decrease symptoms, preserve the CD4 count, and may reduce the size of the latent HIV reservoir. Treatment of patients with acute HIV also reduces the risk of transmitting HIV to others since early HIV infection is associated with high levels of HIV RNA and a corresponding high risk of viral transmission. A detailed discussion of the benefits of treatment in patients with acute HIV is found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3717.html" rel="external">"Acute and early HIV infection: Treatment"</a>.)</p><p class="headingAnchor" id="H84592311"><span class="h3">Patients with opportunistic infections</span><span class="headingEndMark"> — </span>The timing of ART in patients with opportunistic infections is influenced by the type of infection.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Approach for most opportunistic infections</strong> – ART should be initiated within two weeks for most opportunistic infections [<a href="#rid5">5,6,50</a>]. Early initiation of ART is effective in reducing mortality among patients who present with opportunistic infections [<a href="#rid28">28,51-54</a>]. This approach is best supported by the findings from a randomized trial in which 282 patients presenting with various opportunistic infections (two-thirds with <em>Pneumocystis </em>pneumonia) received "early ART" (initiated within 14 days of presentation) or "late ART" (initiated when opportunistic infection treatment was completed) [<a href="#rid28">28</a>]. Early treatment led to a 50 percent reduction in AIDS-related mortality without any increase in treatment-related adverse events or immune reconstitution inflammatory syndrome (IRIS). </p><p></p><p class="bulletIndent1">Early ART is also important for the management of certain infections when specific anti-infective therapy is ineffective or only marginally effective (eg, progressive multifocal leukoencephalopathy, cryptosporidiosis). (See  <a class="medical medical_review" href="/z/d/html/1697.html" rel="external">"Progressive multifocal leukoencephalopathy (PML): Treatment and prognosis"</a> and  <a class="medical medical_review" href="/z/d/html/16217.html" rel="external">"Cryptosporidiosis: Treatment and prevention"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with cryptococcal meningoencephalitis</strong> – In patients with cryptococcal meningoencephalitis, ART should be temporarily delayed since the benefits of early ART are outweighed by induction of a potentially serious IRIS. Trials comparing early versus delayed initiation of ART in patients undergoing treatment for cryptococcal meningoencephalitis consistently show improved survival with delayed initiation. A detailed discussion of when to initiate ART in this setting is presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/83651.html" rel="external">"Cryptococcus neoformans meningoencephalitis in persons with HIV: Treatment and prevention", section on 'When to initiate antiretroviral therapy'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other considerations</strong> – Some experts also delay ART in the setting of certain other opportunistic infections (eg, tuberculosis meningitis, pulmonary tuberculosis in patients with CD4 &gt;50 cells/microL, coccidioidal meningitis) given the potential risk of IRIS and/or concerns for drug interactions that can lead to significant adverse events. However, the benefit of delaying ART in patients with these opportunistic infections has not been definitively established. (See  <a class="medical medical_review" href="/z/d/html/8013.html" rel="external">"Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults with HIV infection: Initiation of therapy"</a> and  <a class="medical medical_review" href="/z/d/html/2418.html" rel="external">"Management considerations, screening, and prevention of coccidioidomycosis in immunocompromised individuals and pregnant patients", section on 'Initiating antiretroviral therapy'</a>.)</p><p></p><p>Additional discussions of when to initiate ART in patients with specific opportunistic infections are presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3709.html" rel="external">"Treatment and prevention of Pneumocystis infection in patients with HIV", section on 'Timing of ART initiation'</a> and  <a class="medical medical_review" href="/z/d/html/3710.html" rel="external">"Toxoplasmosis in patients with HIV", section on 'Antiretroviral therapy'</a> and  <a class="medical medical_review" href="/z/d/html/3731.html" rel="external">"Treatment of AIDS-related cytomegalovirus retinitis", section on 'When to initiate antiretroviral therapy'</a> and  <a class="medical medical_review" href="/z/d/html/3750.html" rel="external">"AIDS-related cytomegalovirus neurologic disease", section on 'When to initiate antiretroviral therapy'</a>.)</p><p class="headingAnchor" id="H9393766"><span class="h3">Pregnant persons</span><span class="headingEndMark"> — </span>ART is recommended for all pregnant persons with HIV to decrease the rate of perinatal HIV transmission and to treat the mother. The evidence for this recommendation, the timing of ART relative to stage of pregnancy, and the choice of agents that are safe in pregnancy are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/13972.html" rel="external">"Prenatal evaluation of women with HIV in resource-rich settings"</a> and  <a class="medical medical_review" href="/z/d/html/15799.html" rel="external">"Antiretroviral selection and management in pregnant individuals with HIV in resource-rich settings"</a>.) </p><p class="headingAnchor" id="H1188796079"><span class="h1">HIV CONTROLLERS</span><span class="headingEndMark"> — </span>A small subset of patients (≤0.5 percent) are able to maintain plasma HIV RNA at levels below the level of detection of standard HIV RNA assays without ART [<a href="#rid55">55</a>]. These patients are sometimes referred to as "HIV controllers." (See  <a class="medical medical_review" href="/z/d/html/3724.html" rel="external">"The natural history and clinical features of HIV infection in adults and adolescents", section on 'HIV controllers'</a>.)</p><p>For such patients, it is not clear if ART is beneficial, and we use a shared decision-making approach to determine if and when ART should be initiated. Patients who are concerned about the potential consequences of even very low-level viral replication and elevated immune activation may opt to start ART, whereas patients who are more concerned about taking a daily regimen and its possible adverse effects without certain benefit may reasonably defer treatment. To engage patients in decision-making, we discuss the following details:</p><p class="bulletIndent1"><span class="glyph">●</span>There are data for increased immune activation, inflammation, and comorbidities in HIV controllers compared with individuals who have a suppressed HIV viral load on ART or individuals without HIV [<a href="#rid56">56,57</a>]. As an example, HIV controllers remain at increased risk for noninfectious complications of HIV, such as cardiovascular disease, compared with the seronegative population [<a href="#rid57">57,58</a>]. In addition, one analysis found an increased frequency of hospitalizations (especially hospitalizations for cardiovascular events) among HIV controllers as compared with individuals with HIV who were virologically suppressed on ART [<a href="#rid59">59</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There are no comparative clinical trial data showing a clinical benefit of ART in HIV controllers, and the effect of ART on immune activation in this setting is unclear. In the START trial described above, which found a reduction in non-AIDS-related events in patients with a CD4 count &gt;500 cells/microL [<a href="#rid11">11</a>], there were few HIV controllers, and there were no changes in markers of inflammation or CD4 count among those who initiated ART [<a href="#rid60">60</a>]. However, in a prospective study of 35 HIV controllers who initiated ART with <a class="drug drug_general" data-topicid="16793" href="/z/d/drug information/16793.html" rel="external">rilpivirine-emtricitabine-tenofovir disoproxil fumarate</a>, treatment reduced T-cell activation and improved markers of immune exhaustion [<a href="#rid61">61</a>]. ART also reduced the viral load as measured by an ultrasensitive assay and was associated with improved quality of life. In both of these studies, the number of HIV controllers was too small and/or the follow-up was too short to assess clinical outcomes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Available antiretroviral drugs are more potent, more convenient, better tolerated, and associated with less toxicity compared with earlier agents, but ART is still associated with a small risk of bone, kidney, and/or other metabolic changes. (See  <a class="medical medical_review" href="/z/d/html/3773.html" rel="external">"Selecting antiretroviral regimens for treatment-naïve persons with HIV-1: General approach", section on 'Commonly used agents'</a> and  <a class="medical medical_review" href="/z/d/html/13978.html" rel="external">"Overview of antiretroviral agents used to treat HIV"</a>.) </p><p></p><p>For those who do not initiate ART, regular monitoring of the CD4 counts and viral loads should be performed. ART should be started in those with decreasing CD4 counts or persistently detectable viremia. A subset of HIV controllers will experience HIV disease progression as evidenced by declining CD4 counts over time [<a href="#rid56">56,62-64</a>], and one small study demonstrated significant CD4 count increases after starting ART [<a href="#rid65">65</a>]. </p><p class="headingAnchor" id="H1561526652"><span class="h1">PATIENTS IN RESOURCE-LIMITED SETTINGS</span><span class="headingEndMark"> — </span>The benefits of antiretroviral therapy (ART) have been demonstrated in widely divergent socioeconomic settings. Thus, indications for therapy do not generally differ in high- and low-resource regions. A discussion of when to initiate therapy in resource-limited settings is found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/13980.html" rel="external">"Use and impact of antiretroviral therapy for HIV infection in resource-limited settings", section on 'Recommendations from the World Health Organization'</a>.)</p><p class="headingAnchor" id="H1429465707"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/111624.html" rel="external">"Society guideline links: HIV treatment in nonpregnant adults and adolescents"</a>.)</p><p class="headingAnchor" id="H41"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15448.html" rel="external">"Patient education: HIV/AIDS (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/16165.html" rel="external">"Patient education: Starting treatment for HIV (The Basics)"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (See  <a class="medical medical_patient" href="/z/d/html/3693.html" rel="external">"Patient education: Initial treatment of HIV (Beyond the Basics)"</a>.)</p><p></p><p class="headingAnchor" id="H42"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Benefit of antiretroviral therapy</strong> – For nearly all persons with HIV, antiretroviral therapy (ART) improves clinical outcomes. Treatment results in sustained suppression of HIV RNA, improved cellular immunity (eg, CD4 count), reduced HIV immune activation (eg, proinflammatory cytokines, chronic inflammation, and T-cell activation), and decreased HIV transmission to others. (See <a class="local">'Universal treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Who should initiate ART</strong> – We recommend ART for patients with HIV infection and a detectable viral load, regardless of CD4 count (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). ART has been found to reduce serious AIDS- and non-AIDS-related complications in patients with a CD4 count &gt;500 cells/microL. In addition, there is high-quality evidence that initiating ART in patients with a CD4 count ≤350 cells/microL results in a significant decline in AIDS-related mortality. (See <a class="local">'Treatment regardless of CD4 count'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Timing of treatment </strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>For most patients</strong> – For most patients who are ready to start treatment, we suggest prescribing ART on the same day of the confirmed diagnosis or within seven days of diagnosis, even before the results of baseline laboratory tests are available (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Regimens used for same-day ART should typically be tenofovir-based and have a high barrier to resistance. (See <a class="local">'Approach for most patients'</a> above and <a class="local">'Patients with acute symptomatic HIV infection'</a> above.)</p><p></p><p class="bulletIndent2">A brief delay in treatment is reasonable in patients who cannot take one of the above regimens, or if there is concern for an active comorbid condition or an active opportunistic infection that makes starting ART logistically difficult (eg, drug interactions or overlapping toxicity). However, most of these patients should initiate ART within two weeks of diagnosis. (See <a class="local">'Approach for most patients'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Selected opportunistic infections</strong> – Rarely, in the setting of specific opportunistic infections (eg, cryptococcal meningitis), treatment should be delayed longer than two weeks. (See <a class="local">'Patients with opportunistic infections'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pregnant persons</strong> – For persons who are pregnant, the timing of ART initiation may depend in part upon the stage of pregnancy. This is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/13972.html" rel="external">"Prenatal evaluation of women with HIV in resource-rich settings"</a> and  <a class="medical medical_review" href="/z/d/html/15799.html" rel="external">"Antiretroviral selection and management in pregnant individuals with HIV in resource-rich settings"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>HIV controllers</strong> – A small subset of patients, referred to as "HIV controllers," maintain plasma HIV RNA at levels that are below the level of detection of available assays without ART. For such patients, it is not clear if ART is beneficial, and we use a shared decision-making approach to determine if and when ART is initiated. Patients who are concerned about the potential consequences of even very low-level viral replication and elevated immune activation may opt to start ART, whereas patients who are more concerned about taking a daily regimen and its possible adverse effects without certain benefit may reasonably defer treatment. (See <a class="local">'HIV controllers'</a> above.) </p><p></p><p class="headingAnchor" id="H3898299579"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges John G Bartlett, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853.</a></li><li><a class="nounderline abstract_t">Marschner IC, Collier AC, Coombs RW, et al. Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. J Infect Dis 1998; 177:40.</a></li><li><a class="nounderline abstract_t">Sterne JA, Hernán MA, Ledergerber B, et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 2005; 366:378.</a></li><li><a class="nounderline abstract_t">Ho DD. Time to hit HIV, early and hard. N Engl J Med 1995; 333:450.</a></li><li><a class="nounderline abstract_t">Gandhi RT, Bedimo R, Hoy JF, et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society-USA Panel. JAMA 2023; 329:63.</a></li><li class="breakAll">Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf (Accessed on March 29, 2022).</li><li><a class="nounderline abstract_t">Samji H, Cescon A, Hogg RS, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One 2013; 8:e81355.</a></li><li><a class="nounderline abstract_t">Lohse N, Obel N. Update of Survival for Persons With HIV Infection in Denmark. Ann Intern Med 2016; 165:749.</a></li><li><a class="nounderline abstract_t">Giorgi JV, Hultin LE, McKeating JA, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 1999; 179:859.</a></li><li><a class="nounderline abstract_t">Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009; 360:1815.</a></li><li><a class="nounderline abstract_t">INSIGHT START Study Group, Lundgren JD, Babiker AG, et al. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med 2015; 373:795.</a></li><li><a class="nounderline abstract_t">TEMPRANO ANRS 12136 Study Group, Danel C, Moh R, et al. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. N Engl J Med 2015; 373:808.</a></li><li><a class="nounderline abstract_t">HIV-CAUSAL Collaboration, Ray M, Logan R, et al. The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS 2010; 24:123.</a></li><li><a class="nounderline abstract_t">Study Group on Death Rates at High CD4 Count in Antiretroviral Naive Patients, Lodwick RK, Sabin CA, et al. Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study. Lancet 2010; 376:340.</a></li><li><a class="nounderline abstract_t">Hogg RS, Yip B, Chan KJ, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001; 286:2568.</a></li><li><a class="nounderline abstract_t">Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337:725.</a></li><li><a class="nounderline abstract_t">Cameron DW, Heath-Chiozzi M, Danner S, et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet 1998; 351:543.</a></li><li><a class="nounderline abstract_t">Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 1987; 317:185.</a></li><li><a class="nounderline abstract_t">When To Start Consortium, Sterne JA, May M, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009; 373:1352.</a></li><li><a class="nounderline abstract_t">Rodríguez B, Sethi AK, Cheruvu VK, et al. Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. JAMA 2006; 296:1498.</a></li><li><a class="nounderline abstract_t">May M, Sterne JA, Sabin C, et al. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS 2007; 21:1185.</a></li><li><a class="nounderline abstract_t">Strategies for Management of Antiretroviral Therapy (SMART) Study Group, Emery S, Neuhaus JA, et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis 2008; 197:1133.</a></li><li><a class="nounderline abstract_t">Jaén A, Esteve A, Miró JM, et al. Determinants of HIV progression and assessment of the optimal time to initiate highly active antiretroviral therapy: PISCIS Cohort (Spain). J Acquir Immune Defic Syndr 2008; 47:212.</a></li><li><a class="nounderline abstract_t">HIV-CAUSAL Collaboration, Cain LE, Logan R, et al. When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. Ann Intern Med 2011; 154:509.</a></li><li><a class="nounderline abstract_t">Phillips AN, Gazzard B, Gilson R, et al. Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count. AIDS 2007; 21:1717.</a></li><li><a class="nounderline abstract_t">Severe P, Juste MA, Ambroise A, et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med 2010; 363:257.</a></li><li><a class="nounderline abstract_t">Grinsztejn B, Hosseinipour MC, Ribaudo HJ, et al. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis 2014; 14:281.</a></li><li><a class="nounderline abstract_t">Zolopa A, Andersen J, Powderly W, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One 2009; 4:e5575.</a></li><li><a class="nounderline abstract_t">Lundgren JD, Babiker AG, Sharma S, et al. Long-Term Benefits from Early Antiretroviral Therapy Initiation in HIV Infection. NEJM Evid 2023; 2.</a></li><li><a class="nounderline abstract_t">Neuhaus J, Angus B, Kowalska JD, et al. Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV. AIDS 2010; 24:697.</a></li><li><a class="nounderline abstract_t">Smith CJ, Ryom L, Weber R, et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet 2014; 384:241.</a></li><li><a class="nounderline abstract_t">Eyawo O, Brockman G, Goldsmith CH, et al. Risk of myocardial infarction among people living with HIV: an updated systematic review and meta-analysis. BMJ Open 2019; 9:e025874.</a></li><li><a class="nounderline abstract_t">Tedaldi E, Peters L, Neuhaus J, et al. Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study. Clin Infect Dis 2008; 47:1468.</a></li><li><a class="nounderline abstract_t">Tedaldi EM, Baker RK, Moorman AC, et al. Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2003; 36:363.</a></li><li><a class="nounderline abstract_t">Bower M, Palmieri C, Dhillon T. AIDS-related malignancies: changing epidemiology and the impact of highly active antiretroviral therapy. Curr Opin Infect Dis 2006; 19:14.</a></li><li><a class="nounderline abstract_t">Borges ÁH, Neuhaus J, Babiker AG, et al. Immediate Antiretroviral Therapy Reduces Risk of Infection-Related Cancer During Early HIV Infection. Clin Infect Dis 2016; 63:1668.</a></li><li><a class="nounderline abstract_t">Koenig SP, Dorvil N, Dévieux JG, et al. Same-day HIV testing with initiation of antiretroviral therapy versus standard care for persons living with HIV: A randomized unblinded trial. PLoS Med 2017; 14:e1002357.</a></li><li><a class="nounderline abstract_t">Ford N, Migone C, Calmy A, et al. Benefits and risks of rapid initiation of antiretroviral therapy. AIDS 2018; 32:17.</a></li><li><a class="nounderline abstract_t">Labhardt ND, Ringera I, Lejone TI, et al. Effect of Offering Same-Day ART vs Usual Health Facility Referral During Home-Based HIV Testing on Linkage to Care and Viral Suppression Among Adults With HIV in Lesotho: The CASCADE Randomized Clinical Trial. JAMA 2018; 319:1103.</a></li><li><a class="nounderline abstract_t">Mateo-Urdiales A, Johnson S, Smith R, et al. Rapid initiation of antiretroviral therapy for people living with HIV. Cochrane Database Syst Rev 2019; 6:CD012962.</a></li><li><a class="nounderline abstract_t">Pilcher CD, Ospina-Norvell C, Dasgupta A, et al. The Effect of Same-Day Observed Initiation of Antiretroviral Therapy on HIV Viral Load and Treatment Outcomes in a US Public Health Setting. J Acquir Immune Defic Syndr 2017; 74:44.</a></li><li><a class="nounderline abstract_t">Colasanti J, Sumitani J, Mehta CC, et al. Implementation of a Rapid Entry Program Decreases Time to Viral Suppression Among Vulnerable Persons Living With HIV in the Southern United States. Open Forum Infect Dis 2018; 5:ofy104.</a></li><li><a class="nounderline abstract_t">Phillips AN, Leen C, Wilson A, et al. Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study. Lancet 2007; 370:1923.</a></li><li><a class="nounderline abstract_t">Khanna N, Opravil M, Furrer H, et al. CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy. Clin Infect Dis 2008; 47:1093.</a></li><li><a class="nounderline abstract_t">Nash D, Katyal M, Brinkhof MW, et al. Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies. AIDS 2008; 22:2291.</a></li><li><a class="nounderline abstract_t">García F, de Lazzari E, Plana M, et al. Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count. J Acquir Immune Defic Syndr 2004; 36:702.</a></li><li><a class="nounderline abstract_t">Mocroft A, Phillips AN, Gatell J, et al. Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. Lancet 2007; 370:407.</a></li><li><a class="nounderline abstract_t">Kelley CF, Kitchen CM, Hunt PW, et al. Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clin Infect Dis 2009; 48:787.</a></li><li><a class="nounderline abstract_t">Engsig FN, Zangerle R, Katsarou O, et al. Long-term mortality in HIV-positive individuals virally suppressed for &gt;3 years with incomplete CD4 recovery. Clin Infect Dis 2014; 58:1312.</a></li><li class="breakAll">Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents:
recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf (Accessed on March 29, 2022).</li><li><a class="nounderline abstract_t">Bicanic T, Meintjes G, Rebe K, et al. Immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis: a prospective study. J Acquir Immune Defic Syndr 2009; 51:130.</a></li><li><a class="nounderline abstract_t">Abdool Karim SS, Naidoo K, Grobler A, et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med 2011; 365:1492.</a></li><li><a class="nounderline abstract_t">Blanc FX, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 2011; 365:1471.</a></li><li><a class="nounderline abstract_t">Havlir DV, Kendall MA, Ive P, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 2011; 365:1482.</a></li><li><a class="nounderline abstract_t">Hatano H, Yukl SA, Ferre AL, et al. Prospective antiretroviral treatment of asymptomatic, HIV-1 infected controllers. PLoS Pathog 2013; 9:e1003691.</a></li><li><a class="nounderline abstract_t">Boufassa F, Saez-Cirion A, Lechenadec J, et al. CD4 dynamics over a 15 year-period among HIV controllers enrolled in the ANRS French observatory. PLoS One 2011; 6:e18726.</a></li><li><a class="nounderline abstract_t">Pereyra F, Lo J, Triant VA, et al. Increased coronary atherosclerosis and immune activation in HIV-1 elite controllers. AIDS 2012; 26:2409.</a></li><li><a class="nounderline abstract_t">Hsue PY, Hunt PW, Schnell A, et al. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS 2009; 23:1059.</a></li><li><a class="nounderline abstract_t">Crowell TA, Gebo KA, Blankson JN, et al. Hospitalization Rates and Reasons Among HIV Elite Controllers and Persons With Medically Controlled HIV Infection. J Infect Dis 2015; 211:1692.</a></li><li><a class="nounderline abstract_t">Sereti I, Gulick RM, Krishnan S, et al. ART in HIV-positive persons with low pre-treatment viremia: results from the START trial. J Acquir Immune Defic Syndr 2019.</a></li><li><a class="nounderline abstract_t">Li JZ, Segal FP, Bosch RJ, et al. Antiretroviral Therapy Reduces T-cell Activation and Immune Exhaustion Markers in Human Immunodeficiency Virus Controllers. Clin Infect Dis 2020; 70:1636.</a></li><li><a class="nounderline abstract_t">Kamya P, Tsoukas CM, Boulet S, et al. T cell Activation does not drive CD4 decline in longitudinally followed HIV-infected Elite Controllers. AIDS Res Ther 2011; 8:20.</a></li><li><a class="nounderline abstract_t">Okulicz JF, Lambotte O. Epidemiology and clinical characteristics of elite controllers. Curr Opin HIV AIDS 2011; 6:163.</a></li><li><a class="nounderline abstract_t">Plaçais L, Boufassa F, Lécuroux C, et al. Antiretroviral therapy for HIV controllers: Reasons for initiation and outcomes in the French ANRS-CO21 CODEX cohort. EClinicalMedicine 2021; 37:100963.</a></li><li><a class="nounderline abstract_t">Okulicz JF, Grandits GA, Weintrob AC, et al. CD4 T cell count reconstitution in HIV controllers after highly active antiretroviral therapy. Clin Infect Dis 2010; 50:1187.</a></li></ol></div><div id="topicVersionRevision">Topic 3777 Version 51.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9516219" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9419168" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16054937" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7616996" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Time to hit HIV, early and hard.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36454551" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society-USA Panel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36454551" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society-USA Panel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24367482" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27842400" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Update of Survival for Persons With HIV Infection in Denmark.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10068581" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19339714" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Effect of early versus deferred antiretroviral therapy for HIV on survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26192873" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26193126" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19770621" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20638118" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11722271" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9287227" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9492772" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3299089" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19361855" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17003398" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17502729" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18476292" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18297762" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Determinants of HIV progression and assessment of the optimal time to initiate highly active antiretroviral therapy: PISCIS Cohort (Spain).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21502648" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17690569" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20647201" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Early versus standard antiretroviral therapy for HIV-infected adults in Haiti.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24602844" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19440326" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37213438" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Long-Term Benefits from Early Antiretroviral Therapy Initiation in HIV Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20177360" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25042234" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31551371" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Risk of myocardial infarction among people living with HIV: an updated systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18959492" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12539079" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16374212" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : AIDS-related malignancies: changing epidemiology and the impact of highly active antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27609756" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Immediate Antiretroviral Therapy Reduces Risk of Infection-Related Cancer During Early HIV Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28742880" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Same-day HIV testing with initiation of antiretroviral therapy versus standard care for persons living with HIV: A randomized unblinded trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29112073" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Benefits and risks of rapid initiation of antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29509839" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Effect of Offering Same-Day ART vs Usual Health Facility Referral During Home-Based HIV Testing on Linkage to Care and Viral Suppression Among Adults With HIV in Lesotho: The CASCADE Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31206168" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Rapid initiation of antiretroviral therapy for people living with HIV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27434707" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : The Effect of Same-Day Observed Initiation of Antiretroviral Therapy on HIV Viral Load and Treatment Outcomes in a US Public Health Setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29992172" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Implementation of a Rapid Entry Program Decreases Time to Viral Suppression Among Vulnerable Persons Living With HIV in the Southern United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18068516" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18783328" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18981768" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15167289" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17659333" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19193107" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24457342" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Long-term mortality in HIV-positive individuals virally suppressed for&gt;3 years with incomplete CD4 recovery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24457342" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Long-term mortality in HIV-positive individuals virally suppressed for&gt;3 years with incomplete CD4 recovery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19365271" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22010915" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Integration of antiretroviral therapy with tuberculosis treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22010913" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22010914" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Timing of antiretroviral therapy for HIV-1 infection and tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24130489" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Prospective antiretroviral treatment of asymptomatic, HIV-1 infected controllers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21533035" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : CD4 dynamics over a 15 year-period among HIV controllers enrolled in the ANRS French observatory.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23032411" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Increased coronary atherosclerosis and immune activation in HIV-1 elite controllers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19390417" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25512624" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Hospitalization Rates and Reasons Among HIV Elite Controllers and Persons With Medically Controlled HIV Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30973544" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : ART in HIV-positive persons with low pre-treatment viremia: results from the START trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31131858" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Antiretroviral Therapy Reduces T-cell Activation and Immune Exhaustion Markers in Human Immunodeficiency Virus Controllers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21679427" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : T cell Activation does not drive CD4 decline in longitudinally followed HIV-infected Elite Controllers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21502920" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Epidemiology and clinical characteristics of elite controllers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34195579" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Antiretroviral therapy for HIV controllers: Reasons for initiation and outcomes in the French ANRS-CO21 CODEX cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20218878" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : CD4 T cell count reconstitution in HIV controllers after highly active antiretroviral therapy.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
